<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451424</url>
  </required_header>
  <id_info>
    <org_study_id>ZPV-200</org_study_id>
    <nct_id>NCT01451424</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids</brief_title>
  <official_title>A Phase 2, 3 Arm, Randomized, Double-Blind Study to Evaluate the Safety, PK and Efficacy of ProellexÂ® Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, pharmacokinetics and efficacy of 4 doses (3, 6, 12, 24 mg) of
      Proellex in premenopausal women with uterine fibroids confirmed by ultrasound. Drug will be
      administered vaginally.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase II, 5 arm study with a 12 week active dosing period. The study will be
      conducted in 2 stages. In the first stage, the first 6 women to be enrolled will be treated
      at the 12mg dose level, and in addition to the other required study assessments will be
      monitored with a 24-hour PK assessment on Day 14, and daily trough assessments for the first
      14 days. If, at Visit 3, the Cmax or AUC of any subject treated at 12mg exceeds the mean
      observed for the highest safe oral dose administered in the ZP-204 study, all subjects
      enrolled at the 12mg level will be discontinued, no further patients will be treated at this
      dose level, and the 6mg vaginal dose will be assessed in a similar fashion. In the second
      stage, the remaining subjects will be randomized to a dose of 3, 6, 12 or 24 mg.

      For all subjects there will be a 4-6 week placebo run-in period, to establish baseline
      parameters (bleeding and quality of life) followed by treatment at one of three single-blind
      Proellex doses (3, 6 or 12 mg daily, administered vaginally in capsule form.) The primary
      efficacy endpoint will be bleeding assessed using the Pictorial Blood Loss Assessment Chart
      (PBAC) after 12 or 16 weeks of treatment. The secondary endpoints will be changes in size of
      uterine fibroids assessed by MRI and improvement in quality of life assessed using the
      Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFSQOL0. Safety
      endpoints include significant adverse events, changes in physical examination results, and/or
      clinical laboratory results significantly outside of normal range. For subjects enrolled in
      Stage 2, PK will be assessed after the first and last doses and trough levels every 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Vaginal Bleeding</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <description>Change from baseline in vaginal bleeding assessed at the end of treatment (12 or 16 weeks) using a Pictorial Blood Loss Assessment Chart (PBAC), which measures volume (mL) of blood loss over a 28-day period
Less blood loss represents an improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Levels of Proellex</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <description>Determination of Cmax of Proellex at end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Fibroid Size</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <description>Percent change in volume of confirmed uterine fibroids at end of treatment, assessed by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induction of Amenorrhea at End of Treatment</measure>
    <time_frame>End of treatment</time_frame>
    <description>Percentage of subjects with induced amenorrhea during last 28 days on drug
Amenorrhea was deemed to be achieved if no daily bleeding score was greater than 1 during the last 28 calendar days of the dosing period. A score of 1 was to be indicated if spotting was observed which did not require a sanitary product. Subjects that terminated early were deemed not to have achieved amenorrhea.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial Thickness</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <description>Percent change in median endometrial thickness from baseline to end of treatment assessed by ultrasound determination of uterine stripe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>12 or 16 weeks</time_frame>
    <description>Percentage change from baseline in median quality of life using uterine fibroid symptom and quality of life questionnaire (UFSQOL)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Proellex 12 mg PK group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 12 mg per protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 6 mg per protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proellex 3 mg per protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 mg Proellex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 mg vaginal Proellex daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex</intervention_name>
    <description>vaginal suppository, daily, for 12 weeks</description>
    <arm_group_label>Proellex 12 mg PK group</arm_group_label>
    <arm_group_label>Proellex 12 mg per protocol</arm_group_label>
    <arm_group_label>Proellex 6 mg per protocol</arm_group_label>
    <arm_group_label>Proellex 3 mg per protocol</arm_group_label>
    <arm_group_label>24 mg Proellex</arm_group_label>
    <other_name>Telapristone acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult females between 18 and 47 years of age with uterine fibroids confirmed
             by ultrasound.

          -  Normal transvaginal ultrasound (other than for presence of fibroids)

          -  History of menstrual events occurring in regular cycles

          -  Agreement not to attempt to become pregnant

          -  Agreement to limit alcohol consumption to no more than 2 drinks per week and to avoid
             alcohol consumption within 48 hours before each visit

          -  Ability to complete a daily subject diary

          -  Willing to discontinue hormonal contraceptives and consent to use of double barrier
             contraceptive techniques over the course of the study.

          -  Has a negative pregnancy test at the Screening and Baseline visits An exception for
             the pregnancy test requirement will be granted for subjects reporting surgical
             sterilization in medical history

          -  A Body Mass Index (BMI) between 18 and 39 inclusive

          -  Is available for all treatment and follow-up visits.

        Exclusion Criteria:

          -  Subject is a post-menopausal woman, defined as either; six (6) months or more
             (immediately prior to screening visit) without a menstrual period, or prior
             hysterectomy and/or oophorectomy

          -  Subject is pregnant or lactating or is attempting or expecting to become pregnant
             during the 6 month study period

          -  Women with abnormally high liver enzymes or liver disease. (ALT or AST exceeding
             1.5xULN AND total bilirubin exceeding 1.5xULN at screening and confirmed on repeat).

          -  Received an investigational drug in the 30 days prior to the screening for this study

          -  Women with a history of PCOS

          -  Concurrent use of any testosterone, progestin, androgen, estrogen, anabolic steroids,
             DHEA or hormonal products for at least 2 weeks prior to screening and during the
             study.

          -  Use of oral contraceptives in the preceding 2 weeks. Use of Depo-ProveraÂ® in the
             preceding 6 months.

          -  Has an IUD in place

          -  Women currently using narcotics

          -  Women currently taking spironolactone

          -  Infectious disease screen is positive for HIV or Hepatitis A, B or C

          -  Clinically significant abnormal findings on screening examination or any condition
             which in the opinion of the investigator would interfere with the participant's
             ability to comply with the study instructions or endanger the participant if she took
             part in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>47 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald D Wiehle, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Health</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Repros Therapeutics Inc corporate website</description>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2014</results_first_posted>
  <last_update_submitted>August 8, 2014</last_update_submitted>
  <last_update_submitted_qc>August 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proellex 3 mg Per Protocol</title>
          <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks
All subjects completed the placebo run-in period and started active dosing.</description>
        </group>
        <group group_id="P2">
          <title>Proellex 6 mg Per Protocol</title>
          <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks
All subjects completed the placebo run-in period and started active dosing.</description>
        </group>
        <group group_id="P3">
          <title>Proellex 12 mg Per Protocol</title>
          <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1, PK group) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks
The first 6 subjects (arm 1) had no placebo run-in period. Arm 3 subjects all completed the placebo run-in period and started active dosing.</description>
        </group>
        <group group_id="P4">
          <title>24 mg Proellex</title>
          <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks
All subjects completed the placebo run-in period and started active dosing.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Proellex 3 mg Per Protocol</title>
          <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Proellex 6 mg Per Protocol</title>
          <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Proellex 12 mg Per Protocol</title>
          <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 weeks Includes subjects from both arms 1 and 3 (PK group and non-PK groups)</description>
        </group>
        <group group_id="B4">
          <title>24 mg Proellex</title>
          <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="6.3"/>
                    <measurement group_id="B2" value="39.9" spread="6.9"/>
                    <measurement group_id="B3" value="39.8" spread="4.8"/>
                    <measurement group_id="B4" value="40.9" spread="5.2"/>
                    <measurement group_id="B5" value="39.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Vaginal Bleeding</title>
        <description>Change from baseline in vaginal bleeding assessed at the end of treatment (12 or 16 weeks) using a Pictorial Blood Loss Assessment Chart (PBAC), which measures volume (mL) of blood loss over a 28-day period
Less blood loss represents an improvement.</description>
        <time_frame>12 or 16 weeks</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vaginal Bleeding</title>
          <description>Change from baseline in vaginal bleeding assessed at the end of treatment (12 or 16 weeks) using a Pictorial Blood Loss Assessment Chart (PBAC), which measures volume (mL) of blood loss over a 28-day period
Less blood loss represents an improvement.</description>
          <population>MITT population</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.5" lower_limit="-102" upper_limit="-4"/>
                    <measurement group_id="O2" value="-36.0" lower_limit="-124" upper_limit="266"/>
                    <measurement group_id="O3" value="-63.5" lower_limit="-242" upper_limit="-14"/>
                    <measurement group_id="O4" value="-39.5" lower_limit="-201" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Levels of Proellex</title>
        <description>Determination of Cmax of Proellex at end of treatment</description>
        <time_frame>12 or 16 weeks</time_frame>
        <population>Subjects with end of treatment PK assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 12 mg PK Group</title>
            <description>Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Levels of Proellex</title>
          <description>Determination of Cmax of Proellex at end of treatment</description>
          <population>Subjects with end of treatment PK assessment</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="5.1"/>
                    <measurement group_id="O2" value="14.1" spread="6.6"/>
                    <measurement group_id="O3" value="11.6" spread="2.0"/>
                    <measurement group_id="O4" value="7.4" spread="5.3"/>
                    <measurement group_id="O5" value="10.2" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uterine Fibroid Size</title>
        <description>Percent change in volume of confirmed uterine fibroids at end of treatment, assessed by MRI</description>
        <time_frame>12 or 16 weeks</time_frame>
        <population>MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Fibroid Size</title>
          <description>Percent change in volume of confirmed uterine fibroids at end of treatment, assessed by MRI</description>
          <population>MITT population</population>
          <units>Percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" lower_limit="-50.7" upper_limit="35.8"/>
                    <measurement group_id="O2" value="-13.4" lower_limit="-28.1" upper_limit="21.3"/>
                    <measurement group_id="O3" value="-21.9" lower_limit="-42.8" upper_limit="-9.6"/>
                    <measurement group_id="O4" value="-3.5" lower_limit="-61.5" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induction of Amenorrhea at End of Treatment</title>
        <description>Percentage of subjects with induced amenorrhea during last 28 days on drug
Amenorrhea was deemed to be achieved if no daily bleeding score was greater than 1 during the last 28 calendar days of the dosing period. A score of 1 was to be indicated if spotting was observed which did not require a sanitary product. Subjects that terminated early were deemed not to have achieved amenorrhea.</description>
        <time_frame>End of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Induction of Amenorrhea at End of Treatment</title>
          <description>Percentage of subjects with induced amenorrhea during last 28 days on drug
Amenorrhea was deemed to be achieved if no daily bleeding score was greater than 1 during the last 28 calendar days of the dosing period. A score of 1 was to be indicated if spotting was observed which did not require a sanitary product. Subjects that terminated early were deemed not to have achieved amenorrhea.</description>
          <units>Percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endometrial Thickness</title>
        <description>Percent change in median endometrial thickness from baseline to end of treatment assessed by ultrasound determination of uterine stripe.</description>
        <time_frame>12 or 16 weeks</time_frame>
        <population>Safety population, data based on subjects with both baseline and end of treatment assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Endometrial Thickness</title>
          <description>Percent change in median endometrial thickness from baseline to end of treatment assessed by ultrasound determination of uterine stripe.</description>
          <population>Safety population, data based on subjects with both baseline and end of treatment assessments</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" lower_limit="-38.1" upper_limit="144"/>
                    <measurement group_id="O2" value="-25.8" lower_limit="-83.8" upper_limit="746.2"/>
                    <measurement group_id="O3" value="39.3" lower_limit="-52.7" upper_limit="243.8"/>
                    <measurement group_id="O4" value="32.3" lower_limit="-64.3" upper_limit="116.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>Percentage change from baseline in median quality of life using uterine fibroid symptom and quality of life questionnaire (UFSQOL)</description>
        <time_frame>12 or 16 weeks</time_frame>
        <population>MITT. Note: lower score is improvement</population>
        <group_list>
          <group group_id="O1">
            <title>Proellex 3 mg Per Protocol</title>
            <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Proellex 6 mg Per Protocol</title>
            <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Proellex 12 mg Per Protocol</title>
            <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 or 16 weeks
Proellex: vaginal suppository, daily, for 12 or 16 weeks
The first 6 subjects dosed at 12 mg (arm 1) were dosed for 16 weeks, the second 6 (arm 3) were dosed for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>24 mg Proellex</title>
            <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>Percentage change from baseline in median quality of life using uterine fibroid symptom and quality of life questionnaire (UFSQOL)</description>
          <population>MITT. Note: lower score is improvement</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.9" lower_limit="-100.0" upper_limit="21.7"/>
                    <measurement group_id="O2" value="-8.5" lower_limit="-100.0" upper_limit="117.4"/>
                    <measurement group_id="O3" value="-98.2" lower_limit="-100.0" upper_limit="-42.9"/>
                    <measurement group_id="O4" value="-100.0" lower_limit="-100.0" upper_limit="-100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Proellex 12 mg Per Protocol Arm/Group includes both Stage 1 and Stage 2 participants, i.e. all subjects dosed at 12 mg</desc>
      <group_list>
        <group group_id="E1">
          <title>Proellex 3 mg Per Protocol</title>
          <description>Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Proellex 6 mg Per Protocol</title>
          <description>Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Proellex 12 mg Per Protocol</title>
          <description>Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>24 mg Proellex</title>
          <description>24 mg vaginal Proellex daily
Proellex: vaginal suppository, daily, for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Treated at 24 mg, considerd by PI to be unrelated to treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <description>Subject treated at 6 mg, considered by PI to be probably related to treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tingling sensation both thighs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vaginal yeast infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Atypical squamous cells of undetermined significance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Trichomonous vaginalis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rask</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsorâs Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsorâs Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

